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In the February issue of Critical Care, Dr McKenzie and
colleagues [1] describe a new method to differentiate
between midazolam over-sedation and neurological damage
in the intensive care unit by measuring 1-hydroxymidazolam
glucuronide (1-OHMG), an active metabolite of midazolam in
serum.
1-OHMG is known to have sedative properties [2,3]. Although
the method described (i.e. high-performance liquid
chromatography coupled to mass spectrometric detection)
might be highly specific and sensitive to detect and quantify
the presence of the 1-OHMG, the presence of an active
substance irrespective of its quantity can never be solely
indicative of a given (patho-)physiological response.
Development of drug tolerance is a basic principle in clinical
pharmacology, the benzodiazepines being a paradigmatic
example. Making dose–response relationship assessment in
vivo is thus very problematic. It is dangerous to rely on
parameters (1-OHMG), even if very carefully measured,
without considering the physiological component/response,
as potentially important decisions could result from a
diagnosis such as neurological damage in the setting of
critical illness. In this regard, flumazenil, a selective
benzodiazepine receptor antagonist, will remain indispensable.
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We thank Dr Kountchev and colleagues for their comments on
our recent publication [1]. We do indeed recognise that drug
tolerance is a well-known pharmacological property of
benzodiazepines. This is borne out by the poor correlation
between the plasma concentrations of midazolam or the
metabolite 1-OHMG [4] and the degree of sedation. In the
context of critical care when neurological outcome is
uncertain, we remain convinced that it is highly desirable to
establish whether the patient’s neurological state can
realistically be attributed to sedative drugs. Even more
importantly, the likelihood of neurological damage is high
when these are not detectable in the plasma — as we have
shown in the paper.
We found the technique we describe clinically useful in the
patients studied, which has informed our decision to seldom
use midazolam in our intensive care unit due to the tendency
for midazolam and its metabolites to accumulate. We did not
dispute that flumazenil has a place in the assessment of
potentially over-sedated patients but, as we pointed out, its
abrupt action and lack of specificity has made it unpopular in
our intensive care unit.
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